Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

March 31, 2022 12:00 ET | Source: Quantum Genomics

Quantum Genomics Announces Publication of a New Scientific Article Featuring QGC606

PARIS, March 31, 2022 (GLOBE NEWSWIRE) -- Quantum Genomics (Euronext Growth : ALQGC, OTCQX : QNNTF), a biopharmaceutical company specializing in the development of a new drug class directly...
March 28, 2022 13:35 ET | Source: Quantum Genomics

Quantum Genomics Announces Granting of New Patents Protecting QGC606

PARIS, March 28, 2022 (GLOBE NEWSWIRE) -- Quantum Genomics (Euronext Growth : ALQGC, OTCQX : QNNTF), a biopharmaceutical company specializing in the development of a new drug class directly...
March 14, 2022 13:00 ET | Source: Quantum Genomics

Stéphane Cohen Joins Quantum Genomics as Director of Global Operations

PARIS, March 14, 2022 (GLOBE NEWSWIRE) -- Quantum Genomics (Euronext Growth – FR0011648971 – ALQGC), a biopharmaceutical company specializing in the development of a new drug class directly...
December 06, 2021 02:00 ET | Source: Quantum Genomics

Quantum Genomics Signs an Exclusive License and Production Agreement with Gulf Pharmaceuticals Industries Julphar

Quantum Genomics will receive up to $20 M in upfront, development and sales milestone payments as well as royalties on future salesJulphar will receive an exclusive license to market firibastat in the...
November 25, 2021 12:00 ET | Source: Quantum Genomics

Quantum Genomics signs an exclusive license agreement with Teva Israel Ltd.

Quantum Genomics will receive up to $11 M in payments and 25% minimum up to 30% royalties on future salesTeva will receive an exclusive license to bring firibastat to its home market, Israel PARIS,...
October 07, 2021 12:00 ET | Source: Quantum Genomics

Quantum Genomics and its Partners Reach a New Stage of Development in Asia

The phase III REFRESH study has been approved by the regulatory authorities and ethics committees in South Korea and Taiwan.Pre-marketing activities have been intensified with OEP and DongWha. PARIS,...
August 27, 2021 04:45 ET | Source: Quantum Genomics

Quantum Genomics Presents Results from Phase IIb QUORUM Study of Firibastat in Heart Failure at the European Society of Cardiology Meeting

Firibastat is as efficient as the current standard of care (ramipril) in preventing the degradation of the left ventricular ejection fraction (primary endpoint) after myocardial infarction in full...
July 08, 2021 02:00 ET | Source: Quantum Genomics

Quantum Genomics Enrolls First Patient in Its Pivotal Phase III REFRESH Trial of Firibastat in Difficult-to-Treat and Resistant Hypertension with Once-a-Day Formulation of Firibastat

PARIS, July 08, 2021 (GLOBE NEWSWIRE) -- Quantum Genomics (Euronext Growth - FR0011648971 - ALQGC), a biopharmaceutical company specializing in developing a new drug class that directly targets the...
July 05, 2021 02:00 ET | Source: Quantum Genomics

Presentation of the Effects of QGC606 in an Experimental Model of Heart Failure at the Annual Congress of the European Society of Cardiology

PARIS, July 05, 2021 (GLOBE NEWSWIRE) -- Quantum Genomics (Euronext Growth - FR0011648971 - ALQGC), biopharmaceutical company specializing in the development of a new class of drugs acting directly...
May 19, 2021 12:40 ET | Source: Quantum Genomics

Quantum Genomics Announces the Publication of New Scientific Article in Biomedicine & Pharmacotherapy Which Further Strengthens its Phase III Development Plan in Difficult to Treat and Resistant Hypertension

PARIS, May 19, 2021 (GLOBE NEWSWIRE) -- Quantum Genomics (Euronext Growth - FR0011648971 - ALQGC), a biopharmaceutical company specializing in the development of a new drug class that directly...